RxDoctor Payments DataLook up a doctor →

Corey Ephrussi, DO

Rheumatology · Greenville, SCNPI 1487883443

Payments from drug & device makers

$53,735in general payments, 2019–2025

Across 708 payments — averaging $75.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$31K
  • AbbVie$7K
  • Boehringer Ingelheim$6K
  • Johnson & Johnson$1K
  • GSK$1K
  • UCB, Inc.$893
  • plus $7K from 27 others

What the payments were for

  • Consulting fees$7,82015%
  • Speaking & faculty fees$27,36851%
  • Travel & lodging$2,6655%
  • Food & beverage$15,65829%
  • Education$2240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,735 in reported general payments places this provider in the 80th percentile of 123 rheumatology providers in South Carolina.

See all rheumatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$4,595,127
Medicare patients
1,035
Services billed
376,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept116$878,108
Humira(Cf) PenAdalimumab39$330,799
Taltz AutoinjectorIxekizumab30$199,891
RinvoqUpadacitinib18$167,062
KevzaraSarilumab25$136,141
Cosentyx Sensoready (2 Pens)Secukinumab14$117,822
Orencia ClickjectAbatacept13$76,260
KineretAnakinra11$59,758
Teriparatide19$39,980
MethotrexateMethotrexate Sodium330$6,182
Prednisone704$4,200
Hydroxychloroquine Sulfate110$3,685
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen150$3,364
Tramadol Hcl222$3,244
Celecoxib111$2,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$6,685$167,06218 claims
SanofiKevzara$278$136,14125 claims
Scilex Pharmaceuticals Inc.Colchicine$62$1,58189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 123 rheumatology providers in South Carolina.

Other rheumatology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →